Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 6/20 | 0.41 |
| ▸ | DRD2 | P14416 | 10/20 | 0.39 |
| ▸ | DRD4 | P21917 | 10/20 | 0.39 |
| ▸ | DRD3 | P35462 | 10/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815505 | 0.73 | POLB (0.40) | — | |
| SCHEMBL14833871 | 0.73 | TRPV6 (0.43) | TRPV6DRD2DRD4DRD3KCNH2 | |
| SCHEMBL14815076 | 0.73 | TRPV6 (0.43) | TRPV6DRD2DRD4DRD3KCNH2 | |
| SCHEMBL14815238 | 0.73 | MAPT (0.47) | ACHEKCNH2 | |
| SCHEMBL14815233 | 0.72 | PKM (0.39) | — | |
| SCHEMBL14815246 | 0.72 | — | — | |
| SCHEMBL14815342 | 0.71 | KDM4E (0.38) | TRPV6 | |
| SCHEMBL14815272 | 0.70 | CCR3 (0.40) | KCNH2 | |
| SCHEMBL14815252 | 0.69 | KMT2A (0.39) | TRPV6KCNH2 | |
| SCHEMBL14815474 | 0.69 | ALDH1A1 (0.45) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | ABBVIE INC. (US) | 2013-04-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085142-A1 | SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1E, CACNA1D | TRPV6 102/4885DRD2 307/4885DRD4 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.